1. EBV-DRIVEN LYMPHOID NEOPLASMS ASSOCIATED WITH ALL MAINTENANCE THERAPY: AN INTERNATIONAL OBSERVATINAL STUDY. (October 2022) Authors: Elitzur, S.; Vora, A.; Burkhardt, B.; Inaba, H.; Attarbaschi, A.; Baruchel, A.; Escherich, G.; Gibson, B.; Liu, H.; Loh, M.; Moorman, A.; Moricke, A.; Pieters, R.; Uyttebroeck, A.; Baird, S.; Bartram, J.; Ben-Harosh, M.; Bertrand, Y.; Buitenkamp, T.; Caldwell, K. Journal: Leukemia research Issue: Volume 121(2022)Supplement Page Start: S5 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: correlations with clinical phenotype and polymorphism of the neonatal Fc receptor. (3rd January 2013) Authors: Gouilleux‐Gruart, V.; Chapel, H.; Chevret, S.; Lucas, M.; Malphettes, M.; Fieschi, C.; Patel, S.; Boutboul, D.; Marson, M.‐N.; Gérard, L.; Lee, M.; Watier, H.; Oksenhendler, E.; Galicier, L.; Fermand, J.P.; Viallard, J.F.; Jaccard, A.; Hoarau, C.; Lebranchu, Y.; Bérezné, A. Journal: Clinical and experimental immunology Issue: Volume 171:Number 2(2013:Feb.) Page Start: 186 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. REDUCED INTENSITY (FB2) VS REDUCED TOXICITY MYELOABLATIVE (FB3‐4) FLUDARABINE/BUSULFAN‐BASED CONDITIONING REGIMENS FOR NON‐HODGKIN LYMPHOMA (NHL) ALLOGRAFTED PATIENTS. (June 2017) Authors: Le Bourgeois, A.; Labopin, M.; Blaise, D.; Ceballos, P.; Vigouroux, S.; Peffault De Latour, R.; Suarez, F.; Bulabois, C.; Bay, J.; Chantepie, S.; Deconinck, E.; Daguindau, E.; Contentin, N.; Yakoub‐Agha, I.; Cornillon, J.; Francois, S.; Turlure, P.; Charbonnier, A.; Rohrlich, P.; N'Guyen, S. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 193 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗